Chordia Therapeutics Restructures Capital to Strengthen Financial Foundation
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chordia Therapeutics Inc. ( (JP:190A) ) has shared an announcement.
Chordia Therapeutics Inc. announced a strategic financial restructuring by reducing its capital reserve to offset current deficits and strengthen its financial foundation. This move aims to enhance the company’s flexibility in future capital policies and optimize its capital structure, without affecting the total net assets or shares issued.
More about Chordia Therapeutics Inc.
Chordia Therapeutics Inc. operates in the pharmaceutical industry, focusing on the development of innovative cancer treatments. Their lead asset, rogocekib (CLK inhibitor CTX-712), is currently in Phase 1/2 clinical trials in the US, targeting cancer vulnerabilities. The company is also developing other assets such as CTX-177, CTX-439, and GCN2 inhibitors.
Average Trading Volume: 797,127
Technical Sentiment Signal: Sell
Current Market Cap: Yen8.1B
See more insights into 190A stock on TipRanks’ Stock Analysis page.
Disclaimer & DisclosureReport an Issue
Trending Articles
- RTO Doesn’t Always Mean RTO: Microsoft Stock (NASDAQ:MSFT) Notches Up as Salespeople Find Exemption
- This Was Not the First Bid: Warner Bros. Discovery Stock (NASDAQ:WBD) Gains as it Rejected Three Bids from Paramount So Far
- ‘Paramount Can Walk Away with Warner Bros.’ Say TD Cowen and Benchmark Analysts
